107 related articles for article (PubMed ID: 4551072)
1. Elimination of 4-n-butoxyphenylacethydroxamic acid (bufexamac) in man.
Boreham DR; Cummings AJ; Della D; Martin BK
J Pharm Sci; 1972 Feb; 61(2):164-8. PubMed ID: 4551072
[No Abstract] [Full Text] [Related]
2. Biodegradations of the hydroxamic acid group of p-n-butoxyphenylacethydroxamic acid (bufexamac) in various animal species.
Roncucci R; Simon MJ; Lambelin G; Buu-Hoï NP
Xenobiotica; 1971; 1(4):567-8. PubMed ID: 5164808
[No Abstract] [Full Text] [Related]
3. Gas-liquid chromatography of hydroxamic acids in biological samples. Detection and quantitation of Bufexamac and one of its major metabolites in plasma and urine.
Roncucci R; Simon MJ; Lambelin G
J Chromatogr; 1971 May; 57(3):410-2. PubMed ID: 5091949
[No Abstract] [Full Text] [Related]
4. Separation and identification of urinary metabolites of 14C-p-n-butoxyphenylacethydroxamic acid in man.
Roncucci R; Simon MJ; Lambelin G; Thiriaux J; Buu-Hoi NP
Biochem Pharmacol; 1968 Feb; 17(2):187-94. PubMed ID: 5647045
[No Abstract] [Full Text] [Related]
5. [Treatment of superficial phlebitis with Bufexamac cream. Cooperative study carried out by 195 physicians with 564 patients].
Reynaers H
Arch Belg Dermatol Syphiligr; 1972; 28(3):279-86. PubMed ID: 4578358
[No Abstract] [Full Text] [Related]
6. [Bufexamac cream and ointment for the treatment of various dermatoses].
Achten G; Bourlond A; Haven E; Lapière CM; Piérard J; Reynaers H
Dermatologica; 1973; 146(1):1-7. PubMed ID: 4571591
[No Abstract] [Full Text] [Related]
7. Estimation of 4-butoyphenylacetohydroxamic acid utilizing the Lossen rearrangement.
Dell D; Boreham DR; Martin BK
J Pharm Sci; 1971 Sep; 60(9):1368-70. PubMed ID: 5567586
[No Abstract] [Full Text] [Related]
8. [Bufexamac, non-steroid anti-inflammatory agent utilizable locally in clinical dermatology].
Achten G; Bourlond A; Haven E; Lapiere C; Pierard J; Reynaers H
Arch Belg Dermatol Syphiligr; 1970; 26(4):509-10. PubMed ID: 5512147
[No Abstract] [Full Text] [Related]
9. Comparative study of bufexamac (Droxaryl) ointment and of its excipient on psoriasis cases: double-blind test.
Van der Meersch J
Curr Ther Res Clin Exp; 1974 Sep; 16(9):904-8. PubMed ID: 4214665
[No Abstract] [Full Text] [Related]
10. [Combined alclofenac-bufexamac in rheumatology].
Famaey JP; Bauduin MP; Wanet G
J Belge Rhumatol Med Phys; 1972; 27(3):110-9. PubMed ID: 4540357
[No Abstract] [Full Text] [Related]
11. [Clinical study of topically administered bufexamac in general practice].
Mathieu R
Schweiz Rundsch Med Prax; 1971 Nov; 60(47):1577-8. PubMed ID: 5140890
[No Abstract] [Full Text] [Related]
12. [Cooperative study of the combination bufexamac-alclofenac in rheumatic diseases].
Famaey JP; Colinet E
J Belge Rhumatol Med Phys; 1971; 26(6):297-311. PubMed ID: 4948861
[No Abstract] [Full Text] [Related]
13. A double-blind clinical study of bufexamac and fluocinolone acetonide in dermatitis.
Mackey JP
J Ir Med Assoc; 1974 Apr; 67(8):214-6. PubMed ID: 4597141
[No Abstract] [Full Text] [Related]
14. In vitro action of bufexamac and selected hydroxamic acids on isolated rat liver lysosomes.
Roncucci R; Lambelin G; Simon MJ; Debast K
Arch Int Pharmacodyn Ther; 1973 Jun; 203(2):348-67. PubMed ID: 4200516
[No Abstract] [Full Text] [Related]
15. [Preliminary study of the action of p-butoxyphenylacethydroxamic acid (Bufexamac) in the treatment of coxarthrosis].
Bloch-Michel H; Parrot M
Therapie; 1970; 25(5):969-75. PubMed ID: 5486155
[No Abstract] [Full Text] [Related]
16. [P-butoxyphenylacethydroxamic acid in analgesic and anti-inflammatory therapy].
Rosoux E
Brux Med; 1969 Jul; 49(7):467-9. PubMed ID: 5402954
[No Abstract] [Full Text] [Related]
17. [p-butoxyphenylacethydroxamic acid in the treatment of rheumatic diseases].
Viara M
Clin Ter; 1974 Jul; 70(2):153-60. PubMed ID: 4408408
[No Abstract] [Full Text] [Related]
18. [Clinical study of topical p-butoxyphenylacethydroxamic acid in physical medicine (Droxyaryl cream)].
Famaey JP
J Belge Rhumatol Med Phys; 1970; 25(5):223-7. PubMed ID: 5514551
[No Abstract] [Full Text] [Related]
19. [1st considerations on the therapeutic contribution of p-butoxyphenylacethydroxamic acid (Droxaryl) in physical medicine].
Paque GR
J Belge Rhumatol Med Phys; 1969; 24(6):273-8. PubMed ID: 5403085
[No Abstract] [Full Text] [Related]
20. Bufexamac in the treatment of skin diseases in general practice.
Valle-Jones JC
Practitioner; 1974 Sep; 213(1275):383-6. PubMed ID: 4609377
[No Abstract] [Full Text] [Related]
[Next] [New Search]
